Abstract: Provided are methods of administering a catechol-O-methyltransferase (COMT) inhibitor chosen from opicapone, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is already being administered quinidine or is suffering from a disease or disorder treatable by quinidine.

Abstract: Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting Axl and BCL-2.

Abstract: The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

Abstract: Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the development of opioid dependence, by preventing the need for dose escalation while either maintaining the opioid analgesic effect or providing analgesia with a lower dose of the opioid. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of opioid use disorders.

Abstract: The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising: (a) netupitant and optionally palonosetron; (b) at least one pharmaceutically acceptable stabilizer; (c) at least one pharmaceutically acceptable solubilizer; and (d) at least one pharmaceutically acceptable vehicle, wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6. The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.

Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer or autoimmune disease in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD20 antibodies. Also provided are medicaments for use in treating cancer or autoimmune disease.

Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.

Abstract: The present disclosure relates to modified nucleoside reverse transcriptase inhibitors (NRTIs), such as and compositions thereof, as well as methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell.

Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.

Abstract: Provided herein are combinations that include a SHP2 inhibitor and a PD-1 inhibitor and methods of treating cancer.

Abstract: A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.

Abstract: An aqueous composition includes a dihydrotriazine compound of the general formula below, where R1 means (i) a phenyl group or phenylalkyl group, (ii) a naphthyl group or naphthylalkyl group, (iii) a heterocyclic group, heterocyclic alkyl group or heterocyclic aminoalkyl group, (iv) an alkyl group having 1 to 16 carbon atoms or (v) a cycloalkyl group or cycloalkylalkyl group, R1? means a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 each mean a hydrogen atom or a methyl group, R4 means an alkyl group having 7 to 16 carbon atoms and the dashed line indicates that a double bond is positioned either between positions 1 and 2 or between positions 2 and 3 of the dihydrotriazine ring, or a tautomer thereof or a salt thereof and a defoamer.

Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Compositions and methods are provided for treating diseases and conditions of the nasal, sinonasal and nasopharyngeal tissues.

Abstract: A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors. The GRM may be, e.g., mifepristone; the CYP3A inhibitors or steroidogenesis inhibitors (collectively “inhibitors”) may be, e.g., ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions; concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to the inhibitors and/or the other drugs. Applicant has surprisingly found that GRMs may be administered to subjects receiving inhibitors without increasing the risk of adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole or itraconazole, providing safe concomitant administration of the GRM and ketoconazole or itraconazole.

Abstract: Disclosed herein are methods for treating estrogen sensitive disease, specifically toward endometrial cancers, and compositions used to treat the estrogen sensitive disease. Methods for treating estrogen sensitive diseases comprise administering to a patient an effective amount of a cannabis extract in the presence of an elevated level of estrogen wherein the estrogen is endogenous estrogen or further comprises exogenous estrogen and wherein the methods may further comprise the addition of a chemotherapeutic agent.

Abstract: The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.

Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2?-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. Leads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.

Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.

Abstract: An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of 1H, 12C, 16O, 14N, 39K, 24Mg, 64Zn, 85Rb, 28Si, 54Fe, 92Mo, 74Se, 58Ni, 70Ge, 52Cr, 63Cu, 50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.

Abstract: The present application relates to a method for reduction and prevention of damaged skin stasis comprising applying a material containing water-soluble or water-insoluble copper compounds to said damaged skin.

Abstract: The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention.

Abstract: The disclosure provides a method of generating non-clustered stem cells. Cluster disruption prior to mesoderm differentiation increases yield and efficiency in hEMP and T cell differentiation. Thus, this method allows the development of improved methods of hEMP and T cell differentiation.

Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: This disclosure provides various TcBuster transposases and transposons, systems, and methods of use.

Abstract: The present disclosure discloses a method for preparing a lysate, from a combination of umbilical cord blood (UCB) and maternal blood (MB) derived platelets by obtaining platelet-rich plasma via sedimentation processes and then mixing platelet-rich plasmas so obtained. The present disclosure further discloses a combination of umbilical cord blood and maternal blood platelet lysate (UCB+MB PL), and the PL so obtained shows greater efficacy as cell and tissue culture media supplement over and above its individual components, umbilical cord blood platelet lysate (UCB PL) and maternal blood platelet lysate (MB PL) and especially over foetal bovine serum (FBS). Moreover, the method of the present disclosure provides an economic, environment friendly, ethical and efficacious method to reach a cell and tissue culture supplement with far-reaching therapeutic applications.

Abstract: The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: Disclosed is a use of a cell wall skeleton of isolated Rhodococcus ruber or a composition containing the same for preparing a human papillomavirus infection treatment drug. The cell wall skeleton of Rhodococcus ruber isolated from Rhodococcus ruber was stored and preserved at China General Microbiological Culture Collection Center, No. 1, West Beichen Road, Chaoyang District, Beijing on Mar. 22, 2019 with accession number CGMCC 17431.

Abstract: Disclosed are compositions for competitive inhibition of pathogens against pathogenic infections comprising (a) Bacillus coagulans; (b) Bacillus subtilis; (c) citric acid; and (d) gallic acid including any combinations thereof. The compositions disclosed in this invention is capable to treat and prevent pathogenic infections of the genital organs as well as suitable for treatment and prevention of dermal infections. A method of preventing recurrence of the infections by way of supporting the growth of inherent natural doderlein microbial populations due to application of the compositions of the present invention are also disclosed. Further, use of the compositions of the present invention obviates the need of prior specific diagnosis of the infections due to its broad spectrum activity against multiple bacterial and fungal pathogens.

Abstract: A system and method for incubating a nutrient spore composition to at least begin the germination process at a point-of-use for small-scale farm applications. The composition comprises solid or powdered L-amino acids, a buffer, optionally D-glucose and/or D-fructose, optionally potassium, and Bacillus spores in a pre-measured filter packet. The method comprises adding a small amount of hot water in a temperature range of 60° C. to 80° C. to the filter packet for an incubation period of around 2 to 60 minutes to form an incubated bacteria solution that is discharged to a farm application. A drip-style coffee maker or similar system may be used to add hot water to the filter packet. The incubated bacteria solution is dispensed to animal drinking water, plants/crops, or an aquaculture pond.

Abstract: Provided are vesicles derived from bacteria of the genus Lactococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease and depression, compared with a normal individual, and the vesicles inhibited the secretion of inflammation mediators caused by pathogenic vesicles. Therefore, it is expected that the vesicles derived from bacteria of the genus Lactococcus can be effectively used for a method of diagnosing diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease or depression, and a composition for preventing or treating the disease or inflammatory disease.

Abstract: A combination of cyanobacteria, chitosan, and plant extracts for wound healing, eliminating pathogen bacteria, or promoting antioxidant activity is provided. The cyanobacteria my be a Spirulina platensis extract and the plant extract may be shilajit.

Abstract: A composition for prevention and treatment of Early Mortality Syndrome (EMS) shrimp to replace antibiotics obtain from process creating a basic mixture by mixing a complex composition with mixing ingredients, then stirring the basic mixture for 1 hour, and adjusting the pH to 6.5-7.5 and leaving it for one day at a temperature of 30° C.-35° C.; wherein the complex composition including 10%-15% by weight of a turkey tail mushroom extract and 10%-15% by weight of a chitosan; in which mixing ingredients consisting of a carboxymethyl cellulose solution 0.375%, a alginate solution 0.375%, a potassium citrate solution, a AgNO3 solution 0.37%, a Cu(NO3)2 solution 0.723%, a Zn(NO3)2 solution 3.085%, Co(NO3)2 solution 0.746%, a Fe(NO3)3 solution 2.5%, a glycerin ingredient, a vitamin E, a tartrazine ingredient 1%, a K2HPO4 solution 15%, a mixture extracts/essential oils, and an other ingredient.

Abstract: An example method of treating or preventing post-operative delirium and cognitive dysfunction and other complications in patients includes administering to a patient a pharmaceutical composition. The composition includes one or more cannabinoid-containing plant compositions having a cannabinoid-containing fraction and a non-cannabinoid containing fraction. The cannabinoid-containing fraction includes Cannabis sativa from C. Indica, C. Ruderalis and their hybrids and various sub species and strains. The non-cannabinoid containing fraction from a Cannabis sativa L. plant and its various sub species and strains.

Abstract: A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.

Abstract: A method of preventing cadmium-induced renal toxicity using a plant product derived from Achillea millefolium L. In an embodiment, the plant product is selected from an extract of Achillea millefolium L and an essential oil of Achillea millefolium L.

Abstract: A composition for treating night blindness includes Coccinia grandis (L.) stem and goat liver for the treatment of night blindness. The composition is edible and demonstrates remarkable therapeutic results when administered to a patient suffering from night blindness. In an embodiment, the composition can cure night blindness within 3 to 5 days of treatment.

Abstract: A subcritical liquid extraction process for the production of oleandrin or oleandrin-containing extract is provided. The process provides improvements over other methods of preparing oleandrin-containing extract. The extract, pharmaceutical compositions, dosage forms and nutraceutical compositions comprising oleandrin or said extract are provided. Methods of treating diseases, disorders or conditions that are therapeutically responsive to oleandrin are also provided.

Abstract: The invention provides a pharmaceutical composition suitable for topical application. The pharmaceutical composition comprises an extract of Plectranthus aliciae and a pharmaceutically acceptable carrier. The invention extends to provide a pharmaceutical composition for the treatment of acne, a pharmaceutical gel composition, a substance or composition comprising an extract of Plectranthus aliciae, a use of a Plectranthus aliciae extract, and various methods of preventing or treating acne.

Abstract: The invention provides to an enriched Withania somnifera (Ashwagandha) extract composition comprising withanolide glycosides, withanolide aglycones and reduced levels of withaferin-A. The invention also provides to process for the preparation of these compositions and further provides to methods of improving testosterone levels, energy levels, sustained energy, vigor, stamina, and muscle mass and muscle strength using these compositions.

Abstract: Disclosed herein are novel compounds that are Ras inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases.

Abstract: This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD, and other inflammatory lung diseases.

Abstract: A previously uncharacterized gene and gene product are disclosed herein that increase blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.